This following article(not peer reviewed yet, in pre-print) is a
multicenter, randomized, placebo-controlled, double-blind, parallel-group trial. It provided a loading dose of hydroxychloroquine (HCQ) 600 mg twice on day 1 followed by 400 mg daily for 29 days or placebo. The outcome was a confirmed or suspected COVID-19 infection. 1360 people participated.

The regimen was safe, no differences in the safety profiles of HCQ and placebo were detected.

Regarding the COVID-19 infection outcome, there was a slight difference in favor of HCQ, however, it was not statistically significant. It would take a larger study to be able to determine if the difference was significative.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.